Gabe Mannis, MD

Treatment Strategies for Relapsed/Refractory AML Patients

December 20th 2024

Panelists discuss how the latest NCCN guidelines for relapsed/refractory acute monocytic leukemia (R/R AML) outline targeted therapy options outside clinical trials, and explore treatment approaches based on patient fitness, actionable biomarkers, and prior therapies, highlighting the impact of first remission duration and genetic abnormalities on treatment sequencing.